<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332016000600495</article-id>
<article-id pub-id-type="doi">10.1016/j.rccar.2016.02.007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Patrón tromboelastográfico en pacientes anticoagulados con rivaroxabán por fibrilaciónauricular]]></article-title>
<article-title xml:lang="en"><![CDATA[Thromboelastographic pattern in anticoagulated patients with rivaroxaban due to atrialfibrillation]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pacheco Jaramillo]]></surname>
<given-names><![CDATA[Susana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Buitrago Sandoval]]></surname>
<given-names><![CDATA[Andrés F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Prada Romero]]></surname>
<given-names><![CDATA[Leidy P.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mojica Manrique]]></surname>
<given-names><![CDATA[Viviana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Raffán Sanabria]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Posada Cortázar]]></surname>
<given-names><![CDATA[Lina V.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Altamar Llanos]]></surname>
<given-names><![CDATA[Henry A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad El Bosque  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Santa Fe de Bogotá  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Fundación Santa Fe de Bogotá Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Fundación Santa Fe de Bogotá  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>23</volume>
<numero>6</numero>
<fpage>495</fpage>
<lpage>499</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332016000600495&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332016000600495&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332016000600495&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  La fibrilación auricular es la arritmia más frecuente y se asocia con mayor riesgo de eventos tromboembólicos, que requieren tratamiento anticoagulante. En la actualidad no existe un examen que permita monitorizar el rango terapéutico cuando se usan nuevos anticoagulantes.  Objetivo:  Describir los patrones tromboelastográficos en los pacientes con fibrilación auricular que reciben terapia de anticoagulación con rivaroxabán del servicio de Cardiología del Hospital Universitario Fundación Santa Fe de Bogotá.  Materiales y métodos:  En este estudio de corte transversal se recolectaron los datos correspondientes a 30 pacientes con fibrilación auricular que recibieron tratamiento anticoagulante con rivaroxabán a partir del 10 de julio de 2013 hasta el 06 de enero de 2015. Se describieron las características generales de la muestra, así como de los parámetros obtenidos por medio del tromboelastograma, y se compararon los patrones de tromboelastografía de acuerdo con la dosis del anticoagulante.  Resultados:  La edad promedio fue 75,8 a&#732;nos y la principal indicación de anticoagulación fue la fibrilación auricular paroxística (56,67%). En más del 60% de los pacientes se obtuvo un tiempo de reacción prolongado y un índice de coagulación bajo. El resto de parámetros del tromboelastograma se encontraban dentro del rango normal en la mayoría de los casos. No hubo diferencias estadísticamente significativas en los parámetros del tromboelastograma al comparar la dosis de rivaroxabán de 15 mg versus 20 mg.  Conclusión:  El patrón tromboelastográfico obtenido en la mayoría de pacientes del estudio se caracterizó por un tiempo de reacción alto y un índice de coagulación bajo, posiblemente debido al efecto del inhibidor del factor Xa.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Atrial fibrillation is the most common arrhythmia, and it is associated with a higher risk of thromboembolic events requiring anticoagulation therapy. Nowadays there is no test that allows monitoring the therapeutic range when using new anticoagulants.  Motivation:  To describe thromboelastographic patterns in patients with atrial fibrillation who are taking anticoagulants with rivaroxaban in the Cardiology Department at the University Hospital Fundación Santa Fe de Bogotá.  Material and methods:  The present cross-sectional study collected data relating to 30 patients with atrial fibrillation who received anticoagulation therapy with rivaroxaban between July 10th 2013 and January 6th 2015.General characteristics of the sample, as well as paramametres obtained from the thromboelastography, and they were compared to the thromboelastographic patterns according to the anticoagulant dose.  Results:  Average age was 75.8 years and the main indication for anticoagulation therapy was paroxysmal atrial fibrillation (56.67%). In more than 60% of patients a prolonged reaction time and low coagulation index was obtained. The remaining parametres from the thromboelastography were located within the normal range in most cases. No statistically significant differences were found in thromboelastographic patterns when comparing the 15 mg versus 20 mg rivaroxaban dose.  Conclusion:  Thromboelastographic patterns obtained in most study participants were characterized by a high reaction time and low coagulation index, possibly due to the effect of the factor Xa inhibitor.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Fibrilación auricular]]></kwd>
<kwd lng="es"><![CDATA[Tratamiento anticoagulante]]></kwd>
<kwd lng="es"><![CDATA[Anticoagulantes]]></kwd>
<kwd lng="es"><![CDATA[Coagulación.]]></kwd>
<kwd lng="en"><![CDATA[Atrial fibrillation]]></kwd>
<kwd lng="en"><![CDATA[Anticoagulation therapy]]></kwd>
<kwd lng="en"><![CDATA[Anticoagulants]]></kwd>
<kwd lng="en"><![CDATA[Coagulation]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Hole]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Heart]]></source>
<year>2001</year>
<volume>86</volume>
<page-range>516-21</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Outcome parameters for trials in atrial fibrillation executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Auricchio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bax]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hohnloser]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kuck]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Meinertz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J]]></source>
<year>2007</year>
<volume>28</volume>
<page-range>2803-17</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rivaroxaban-once daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Rationale and Design of the ROCKET AF study]]></article-title>
<collab>ROCKET AF Study Investigators</collab>
<source><![CDATA[Am Heart J]]></source>
<year>2010</year>
<volume>159</volume>
<page-range>340-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rivaroxaban versus warfarin in nonvalvular atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Hacke]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>365</volume>
<page-range>883-91</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tromboelastografía]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raffán]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cuervo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Col Anest]]></source>
<year>2005</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>181-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Meta-analysis antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Pearce]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>2007</year>
<volume>146</volume>
<page-range>857-67</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[TEG and ROTEM technology and clinical applications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whiting]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[DiNardo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Hematol]]></source>
<year>2014</year>
<volume>89</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>228-32</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Use of thromboelastography (TEG) for detection of new oral anticoagulants]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Norem]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Doorneweerd]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Thurer]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Popovsky]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Omert]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Pathol Lab Med]]></source>
<year>2015</year>
<volume>139</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>665-73</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bowry]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Archeval-Lao]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rahbar]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<source><![CDATA[Stroke]]></source>
<year>2014</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>880-3</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEMTM]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casutt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Konrad]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schuepfer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Anaesthesist]]></source>
<year>2012</year>
<volume>61</volume>
<page-range>948-53</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
